Bryan Durkin Acquires Shares of CME Group Inc.
Bryan Durkin bought 645 shares of CME Group Inc., valued at $145,125.
Key Points
- Bryan Durkin purchased 645 shares of CME Group Inc. on June 25, 2026, for $225 each, totaling $145,125.
- CME Group Inc., with a market cap of $79.9 billion, trades near $221. It has a P/E ratio of 18.9 and a 52-week range of $220.73 to $329.16.
- Rothschild & Co upgraded CME Group to a 'buy' with a $323 price target on June 11, 2026, while Morgan Stanley maintains a $353 target.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Bryan Durkin, a notable insider, recently made a purchase of CME Group Inc.'s stock. On June 25, 2026, he bought 645 shares at an average price of $225 each, totaling $145,125. This transaction was not part of a pre-planned trading arrangement.
What Changed in Bryan Durkin's CME Group Position
Bryan Durkin's acquisition of CME Group shares adds to his holdings in the company. By purchasing 645 shares at $225 each, Durkin's investment totaled $145,125. This move indicates his confidence in the company's future prospects.
Other Institutional Activity in CME Group
In recent activity, BlackRock, Inc. increased its holdings in CME Group by 370,381 shares, bringing its total to 31,448,257 shares worth approximately $9.29 billion, a 1.2% increase. Vanguard Capital Management LLC opened a new position with 23,367,282 shares valued at about $6.90 billion. State Street Corp reduced its stake by 89,238 shares, ending with 16,055,287 shares valued at $4.74 billion, marking a 0.6% decrease. JPMorgan Chase & Co added 1,108,304 shares, increasing its holdings by 10% to 12,209,761 shares valued at $3.63 billion. Morgan Stanley also boosted its stake by 1,043,692 shares, a 12.5% increase, bringing its total to 9,406,843 shares worth $2.78 billion.
CME Group Inc. Stock Down 23.5%
Shares of NasdaqGS:CME traded near $221 on Tuesday. CME Group Inc. has a market capitalization of $79.9 billion and a P/E ratio of 18.9. The stock has a 52-week low of $220.73 and a high of $329.16. Its 50-day moving average is $273.98, and the 200-day moving average is $280.89. The company has a current ratio of 1.02, a quick ratio of 0.02, and a debt-to-equity ratio of 14.06.
$CME stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
CME Group reported revenue of $6.74 billion with a growth rate of 14.4%. The company's earnings per share stand at $11.71, with a net margin of 63.3% and a return on equity of 15.9%. The next earnings announcement is scheduled for July 22, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
2 target cuts vs 0 raises.
-
EPS & revenue
EPS missed estimates by 1.2%. Revenue missed estimates by 1.6%.
-
Profit surprise
EBITDA missed by 6 percent. Operating income missed by 5 percent.
-
Pre-earnings setup
Expectations were about average.
-
Analyst signal
2 target cuts.
-
Earnings quality
Gross margin up 0.7 points. Operating margin up 2.2 points. Positive free cash flow.
Earnings Call Summary
CME delivered a record first quarter with average daily volume of 36.2 million contracts, up 22 percent year-over-year, marking the highest in company history. Revenue reached $1.88 billion, up 14 percent, with record performance across all six asset classes and international markets. The company achieved record adjusted operating margins of 72.8 percent and adjusted earnings per share of $3.36, returning $3.2 billion to shareholders through dividends and buybacks.
Guidance CME reaffirmed its full-year adjusted expense guidance of about $1.695 billion. The company expects to continue investing in technology and cloud migration while maintaining capital returns through dividends and share buybacks.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
CME Group pays an annual dividend rate of $5.20, offering a yield of 2.35%. The dividend payout ratio is quite high at 95.6%.
Insider Buying and Selling at CME Group Inc.
Several insiders, including Phyllis Lockett, Howard Siegel, William Shepard, Rahael Seifu, Bryan Durkin, and Patrick Maloney, purchased shares on June 25, 2026. Each insider bought 645 shares at a price of $225 per share, with no transactions being part of a pre-planned trading scheme.
Analysts Set New Price Targets
On June 11, 2026, Rothschild & Co upgraded CME Group to a 'buy' rating with a price target of $323. Morgan Stanley maintained its 'buy' rating with a target of $353, while Barclays continues to hold a 'hold' rating with a target of $316. The consensus recommendation is a 'buy', with an average target price of $302.60 based on 15 analyst opinions.
About CME Group Inc.
CME Group Inc. operates global markets for trading futures and options on various asset classes, including interest rates, equity indexes, foreign exchange, and commodities. Headquartered in Chicago, Illinois, and led by CEO Mr. Terrence A. Duffy, the company employs 3,875 people. It also provides clearing services and market data solutions, catering to professional traders, financial institutions, and individual investors worldwide.
Bottom Line
Bryan Durkin's recent share purchase is a notable development for CME Group Inc., reflecting insider confidence. The company's strong market position, coupled with analyst upgrades, makes it a stock to watch. However, it's important to note that insider transactions like Durkin's are disclosed after the fact and may not indicate current or future positions.
Get CME Group Inc. alerts
New 13F filings, insider trades, and analyst moves on $CME, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.